|
J&J’s Canagliflozin May Be More Effective Than AZ, BMS’ Dapagliflozin: Analyst
Johnson & Johnson’s (J&J) Type 2 diabetes treatment canagliflozin appears to have a “modestly better” efficacy profile compared with its competitor, AstraZeneca and Bristol Myers Squibb’s (BMS) Forxiga, as the companies race to bring the first selective sodium glucose co-transport 2 (SGLT-2) inhibitor to market, an analyst says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives